Accéder directement au contenu Accéder directement à la navigation
Chapitre d'ouvrage

Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease

Abstract : In patients with chronic kidney disease (CKD), uremic toxins constitute a specific non-traditional risk factor. Research in this field started in the early 1990s, and a growing body of preclinical and epidemiological evidence suggests that elevated levels of uremic toxins are associated with poor outcomes in a CKD setting. The present review focuses on a specific class of uremic toxins (the ``middle molecules''), which includes well-known candidates like beta-2 microglobulin and fibroblast growth factor 23. Here, we summarize the epidemiological evidence linking the middle-molecule uremic toxin (and especially the larger ones) with hard clinical end points. Our findings highlight the urgent need for clinical trials of interventions designed to decrease levels of these middle molecules in CKD patients. (c) 2017 S. Karger AG, Basel
Type de document :
Chapitre d'ouvrage
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : jeudi 17 février 2022 - 16:02:51
Dernière modification le : vendredi 5 août 2022 - 11:25:23

Lien texte intégral



Ziad A. Massy, Sophie Liabeuf. Middle-Molecule Uremic Toxins and Outcomes in Chronic Kidney Disease. Ronco, C. EXPANDED HEMODIALYSIS: INNOVATIVE CLINICAL APPROACH IN DIALYSIS, 191, pp.8-17, 2017, Contributions to Nephrology, 978-3-318-06117-8; 978-3-318-06116-1. ⟨10.1159/000479252⟩. ⟨hal-03578873⟩



Consultations de la notice